- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Biotech Firm Cuts 63 Jobs in Woburn After FDA Setback
Replimune scales back U.S. manufacturing and development plans following regulatory decision on cancer therapy
Apr. 15, 2026 at 6:07am
Got story updates? Submit your updates here. ›
The FDA's decision on Replimune's cancer therapy has led to significant job losses in Woburn's biotech community.Cambridge TodayReplimune, a cancer therapy developer, is cutting 63 jobs at its Woburn facility this month after the FDA stalled approval of the company's RP1 cancer treatment, prompting the biotech firm to scale back its U.S. manufacturing and reconsider its development plans.
Why it matters
The layoffs are a major blow for local biotech workers and their families in the Woburn area, which has seen significant growth in the life sciences industry in recent years. The FDA's decision on Replimune's cancer therapy highlights the risks and uncertainties that biotech companies face in the drug development process.
The details
Replimune is cutting 63 jobs at its Woburn facility this month following an FDA decision that stalled approval of the company's RP1 cancer therapy. The layoffs have prompted Replimune to scale back its U.S. manufacturing operations and reconsider its overall development plans for the treatment.
- Replimune announced the job cuts at its Woburn facility in April 2026.
- The FDA decision that led to the layoffs occurred earlier in 2026.
The players
Replimune
A cancer therapy developer that is cutting 63 jobs at its Woburn, Massachusetts facility.
What’s next
Replimune is expected to provide updates on its development plans for RP1 and any potential regulatory path forward in the coming months.
The takeaway
The Replimune job cuts highlight the challenges biotech companies face in navigating the drug approval process and the impact that regulatory decisions can have on local economies and workforces.
